Recombinant Human CD300a Protein (Fc Tag His Tag)
Beta LifeScience
SKU/CAT #: BLA-10957P
Recombinant Human CD300a Protein (Fc Tag His Tag)
Beta LifeScience
SKU/CAT #: BLA-10957P
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Host Species | Human |
Accession | Q9UGN4 |
Synonym | CD300 antigen-like family member A CD300a CD300a antigen CD300a molecule CLM-8 CLM8_HUMAN CMRF 35 H9 CMRF-35-H9 CMRF35-H CMRF35-H9 CMRF35-like molecule 8 CMRF35H CMRF35H leukocyte immunoglobulin like receptor CMRF35H9 IgSF12 Immunoglobulin superfamily member 12 Inhibitory receptor protein 60 IRC1 IRC1/IRC2 IRC2 IRp60 Leukocyte membrane antigen Mast cell derived paired immunoglobulin like receptor 1 NK inhibitory receptor Polymeric immunoglobulin receptor 4 |
Description | Recombinant Human CD300a Protein (Fc Tag His Tag) was expressed in Mammalian. It is a Protein fragment |
Source | Mammalian |
AA Sequence | LSKCRTVAGPVGGSLSVQCPYEKEHRTLNKYWCRPPQIFLCDKIVETKGS AGKRNGRVSIRDSPANLSFTVTLENLTEEDAGTYWCGVDTPWLRDFHDPV VEVEVSVFPASTSMTPASITAAKTSTITTAFPPVSSTTLFAVGATHSASI QEETEEVVNSQVDDIEGRMDEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE PQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP GKHHHHHH |
Molecular Weight | 45 kDa including tags |
Purity | >95% SDS-PAGE.Purity is greater than 95% as determined by SEC-HPLC and reducing SDS-PAGE. |
Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method |
Formulation | Lyophilised |
Stability | The recombinant protein samples are stable for up to 12 months at -80°C |
Reconstitution | See related COA |
Unit Definition | For Research Use Only |
Storage Buffer | Shipped at 4°C. Store at -80°C. Avoid freeze / thaw cycle. |